Full Text View
Tabular View
No Study Results Posted
Related Studies
Inappropriate Medications Associated With Anticholinesterase and/or Memantine Treatment in the Elderly (MIDA)
This study is currently recruiting participants.
Verified by University Hospital, Limoges, August 2009
First Received: July 31, 2009   Last Updated: August 5, 2009   History of Changes
Sponsored by: University Hospital, Limoges
Information provided by: University Hospital, Limoges
ClinicalTrials.gov Identifier: NCT00954616
  Purpose

In each of the 7 French areas that should be involved, patients aged 75 years and over from three different sectors will be included: the geriatric consultation unit (60%) and two kinds of nursing homes, private (20%) and state (10%). Outpatients will be included in chronological order; patients in nursing homes will be included at random. The patients and their families will be asked about the treatments received on the day of inclusion. The inclusion period will extend over a year. The investigating practitioners will be asked to fill in a questionnaire reporting the main clinical data, adverse effects occurrence, and information on the treatment given.


Condition
Alzheimer's Disease

Study Type: Observational
Study Design: Case-Only, Prospective
Official Title: Inappropriate Medications and Alzheimer Disease: Prevalence and Associated Factors in Elderly Patients Treated With Anticholinesterase and/or Memantine. MIDA Study.

Resource links provided by NLM:


Further study details as provided by University Hospital, Limoges:

Primary Outcome Measures:
  • To evaluate the prevalence of PIM use in patients aged 75 years and over treated with anticholinesterase and/or memantine [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To identify factors associated with PIM use. To study the relationship between PIM exposure and adverse effects occurrence. [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   None Retained

Biospecimen Description:

Estimated Enrollment: 700
Study Start Date: January 2009
Estimated Study Completion Date: January 2011
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   75 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patient of 75 and more years old affected by the Alzheimer's disease

Criteria

Inclusion Criteria:

  • Patients aged 75 years and over identified as having Alzheimer disease and who have been treated for more than 3 months with anticholinesterase and/or memantine

Exclusion Criteria:

  • Patients with decompensated chronic condition or acute phase disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00954616

Contacts
Contact: Marie - Laure LAROCHE, Doctor 0555056743 marie-laure.laroche@chu-limoges.fr

Locations
France
CHU Saint Etienne Recruiting
Saint Etienne, France, 42 055
Contact: Catherine TERRAT, Doctor            
Principal Investigator: Catherine TERRAT, Doctor            
France, Bois guillaume
CHU Rouen Recruiting
Rouen, Bois guillaume, France, 76 230
Contact: Jean DOUCET, Porfessor     02 32 88 90 42        
Principal Investigator: Jean DOUCET, Professor            
France, Bordeaux
CHU Bordeaux Recruiting
Pessac, Bordeaux, France, 33 604
Contact: Muriel RAINFRAY, Professor            
Principal Investigator: Muriel RAINFRAY, Professor            
France, Le Mans Cedex 1
CH Le Mans Recruiting
Le Mans, Le Mans Cedex 1, France, 72 037
Contact: Emmanuel ALIX, Doctor            
Principal Investigator: Emmanuel ALIX, Doctor            
France, Montpellier Cedex 5
CHU Montpellier Recruiting
Montpellier, Montpellier Cedex 5, France, 34 295
Contact: Claude JEANDEL, Professor     04 67 33 96 01        
Principal Investigator: Claude JEANDEL, Professor            
France, Paris
APHP Charles Foix Recruiting
Ivry sur Seine, Paris, France, 94 205
Contact: Aurora LALHOU, Doctor            
Principal Investigator: Aurora LALHOU, Doctor            
Sponsors and Collaborators
University Hospital, Limoges
  More Information

No publications provided

Responsible Party: CHU Limoges ( Marie Sengelen / Directrice de la Recherche clinique et de l'Innovation )
Study ID Numbers: I07033
Study First Received: July 31, 2009
Last Updated: August 5, 2009
ClinicalTrials.gov Identifier: NCT00954616     History of Changes
Health Authority: France: Afssaps - French Health Products Safety Agency

Keywords provided by University Hospital, Limoges:
Inappropriate Medications Associated
Alzheimer's disease

Study placed in the following topic categories:
Neurotransmitter Agents
Alzheimer Disease
Central Nervous System Diseases
Brain Diseases
Neurodegenerative Diseases
Cholinergic Agents
Cognition Disorders
Cholinesterase Inhibitors
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Memantine
Dementia
Delirium

Additional relevant MeSH terms:
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Alzheimer Disease
Nervous System Diseases
Central Nervous System Diseases
Enzyme Inhibitors
Cholinergic Agents
Brain Diseases
Neurodegenerative Diseases
Pharmacologic Actions
Cholinesterase Inhibitors
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Dementia
Tauopathies

ClinicalTrials.gov processed this record on September 11, 2009